• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

41.03 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
April 29, 2025
 
Via Benzinga
News headline image
Apellis Announces Craig Wheeler to Join the Board of Directors
April 21, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗
April 01, 2025
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
News headline image
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
April 01, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗
March 03, 2025
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
February 13, 2025
 
Via Benzinga
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
March 18, 2025
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
News headline image
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗
March 05, 2025
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 28, 2025 ↗
February 28, 2025
 
Via Benzinga
News headline image
Analyst Expectations For Apellis Pharmaceuticals's Future ↗
January 21, 2025
 
Via Benzinga
News headline image
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) ↗
December 17, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
February 20, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 14, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts ↗
November 21, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
January 27, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Keli Walbert to Join the Board of Directors
January 10, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 23, 2024
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
December 17, 2024
 
Via Benzinga
News headline image
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
December 17, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 27, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday ↗
November 19, 2024
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
November 12, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
November 06, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap